CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 515-531

  Hanagata, Nobutaka ^a,b  

^a NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Adjuvant; CpG oligodeoxynucleotides; Immunostimulation; Nanomedicine; Toll like receptor 9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; NANOMATERIAL; TOLL LIKE RECEPTOR 9; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE;

ALLERGY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; COMPLEX FORMATION; DRUG CONJUGATION; DRUG EFFICACY; HUMAN; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; MALIGNANT NEOPLASM; NANOMEDICINE; NONHUMAN; REVIEW; ANIMAL; COMMUNICABLE DISEASES; HYPERSENSITIVITY; NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; COMMUNICABLE DISEASES; HUMANS; HYPERSENSITIVITY; NANOMEDICINE; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 85010288632     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S114477     Document Type: Review

References (115)

1. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740–745.
2. Takeshita F, Leifer CA, Gursel I, et al. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol. 2001;167(7):3555–3558.
3. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides. J Leukoc Biol. 2002;71(5):813–820.
4. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168(9):4531–4537.
5. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194(6):863–869.
6. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001;31(10):3026–3037.
7. Bauer M, Redecke V, Ellwart JW, et al. Bacterial CpG DNA triggers activation and maturation of human CD11c(−), CD123(+) dendritic cells. J Immunol. 2001;166(8):5000–5007.
8. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499–511.
9. Shirota H, Klinman DM. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines. 2014;13(2):299–312.
10. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709–760.
11. Gürsel M, Verthelyi D, Gürsel I, Ishii KJ, Klinman DM. Differential and competitive activation of human immune cells by distinct classes of CpG oligonucleotide. J Leukoc Biol. 2002;71(5):813–820.
12. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164(3):1617–1624.
13. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164(2):944–953.
14. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988;16(8):3209–3221.
15. Shaw JP, Kent K, Bird J, Fishback J, Froehler B. Modified deoxynucleotides stable to exonuclease degradation in serum. Nucleic Acids Res. 1991;19(4):747–750.
16. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 2004;97(1):1–17.
17. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001;31(7):2154–2163.
18. Kerkmann M, Costa LT, Richter C, et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem. 2005;280(9):8086–8093.
19. Klein DC, Latz E, Espevik T, Stokke BT. Higher order structure of short immunostimulatory oligonucleotides studied by atomic force microscopy. Ultramicroscopy. 2010;110(6):689–693.
20. Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood. 1998;92(5):1617–1625.
21. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 1997;7(5):503–510.
22. Shaw DR, Rustagi PK, Kandimalla ER, Manning AN, Jiang Z, Agrawal S. Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol. 1997;53:1123–1132.
23. Brown DA, Kang SH, Gryaznov SM, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem. 1994;269(43):26801–26805.
24. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta. 1999;1489(1):69–84.
25. Henry SP, Beattie G, Yeh G, et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol. 2002;2(12):1657–1666.
26. Agrawal S, Zhao Q, Jiang Z, et al. Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev. 1997;7(6):575–584.
27. Bjersing JL, Eriksson K, Tarkowski A, Collins LV. The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs. Inflammation. 2004;28(1):39–51.
28. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004;10(2):187–192.
29. Chinnathambi S, Chen S, Ganesan S, Hanagata N. Binding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via Toll-like receptor 9. Sci Rep. 2012;2:534.
30. Chinnathambi S, Pi X, Xu M, Hanagata N. Regulation of bifurcated cytokine induction by surface charge of nanoparticles during interaction between CpG oligodeoxynucleotides and toll-like receptor 9. J Drug Deliv Sci Technol. 2015;29:251–260.
31. Haas T, Schmitz F, Heit A, Wagner H. Sequence independent interferon-alpha induction by multimerized phosphodiester DNA depends on spatial regulation of Toll-like receptor-9 activation in plasmacytoid dendritic cells. Immunology. 2009;126(2):290–298.
32. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564–569.
33. Schmidt NW, Jin F, Lande R. Liquid-crystalline ordering of antimicrobial peptide-DNA complexes controls TLR9 activation. Nat Mater. 2015;14:696–700.
34. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70(21):8368–8377.
35. Vacchelli E, Pol J, Bloy N, et al. Trial watch: tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology. 2015;4(1):e985940.
36. Xie Y, Akpinarli A, Maris C. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010;207(3):651–667.
37. Braumüller H, Wieder T, Brenner E, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494:361–365.
38. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potential signal for growth, activation and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999;96(16):9305–9310.
39. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementary in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol. 2001;31(11):3388–3393.
40. Kerkmann M, Rothenfusser S, Hornung V, et al. Activation with CpG-A and CpG-B oligodeoxynucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol. 2003;170(9):4465–4474.
41. Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003;23(3):147–161.
42. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev. 2008;60(7):795–804.
43. Hervas-Stubbs S, Riezu-Boj JI, Gonzalez I, et al. Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8+ T cells. Eur J Immunol. 2010;40(12):3389–3402.
44. Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology. 2011;132(4):466–474.
45. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637–650.
46. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations in synergistically trigger a T helper type I-polarizing program in dendritic cells. Nat Immunol. 2005;6(8):769–776.
47. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1promoting adjuvants. Nat Med. 1997;3(8):849–854.
48. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996;157(5):1840–1845.
49. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol. 2012;188:1592–1599.
50. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells. Blood. 2003;101(11):4500–4504.
51. Ruprecht CR, Lamzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naïve B cells. Eur J Immunol. 2006;36(4):810–816.
52. Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood. 2009;113(17):3969–3977.
53. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546–548.
54. Davis HL, Weeranta R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998;160(2):870–876.
55. Kobayashi H, Horner AA, Takabayashi K, et al. Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell Immunol. 1999;198(1):69–75.
56. Jung J, Yi AK, Zhang X, Choe J, Li L, Choi YS. Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J Immunol. 2002;169(5):2368–2373.
57. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996;93(7):2879–2883.
58. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.
59. Bernasconi HL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002;298(5601):2199–2202.
60. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5(6):471–484.
61. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. 2012;18(5):684–692.
62. Johnson J, Wiley RE, Fattouh R, et al. Continous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care. 2004;169(3):378–385.
63. Busse WW, lemanske RF Jr. Asthma. N Engl Med. 2001;344(5):350–362.
64. Mazzarella G, Bianco A, Catena E, De Palma R, Abbate GF. Th1/Th2 lymphocyte polarization in asthma. Allergy. 2000;55(Suppl 61):6–9.
65. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255–281.
66. Wohleben G, Erk KJ. Atopic disorders: a vaccine around the corner? Trends Immunol. 2001;22(11):618–626.
67. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(Suppl 1):S1–S55.
68. Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008;21(8):434–439.
69. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009;61(3):256–262.
70. Pulsawat P, Pitakpolrat P, Prompetchara E, et al. Optimization of a Der p 2-biased prophylactic DNA vaccine against house dust mite allergy. Immunol Lett. 2013;151(1–2):23–30.
71. Heeg K, Zimmermann S. CpG DNA as a Th1 trigger. Int Arch Allergy Immunol. 2000;121(2):87–97.
72. Mo JH, Park SW, Rhee CS, et al. Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis. Am J Rhinol. 2006;20(2):212–218.
73. Li J, Pei H, Zhu B, et al. Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. ACS Nano. 2011;5(11):8783–8789.
74. Schmidt M, Anton K, Nordhaus C, Junghans C, Wittig B, Worm M. Cytokine and Ig-production by CpG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy. 2006;61(1):56–63.
75. Schmidt M, Hagner N, Marco A, Konig-Merediz SA, Schroff M, Wittig B. Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703. Nucleic Acid Ther. 2015;25(3):130–140.
76. Weihrauch MR, Richly H, von Bergwelt-Baildon MS, et al. Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors. Eur J Cancer. 2015;51(2):146–156.
77. Schmoll H-J, Wittig B, Arnold D, et al. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Oncol. 2014;140(9):1615–1624.
78. Koo J-E, Shin S-W, Um S-H, Lee J-Y. X-shaped DNA potentiates therapeutic efficacy in colitis-associated colon cancer through dual activation of TLR9 and inflammasomes. Mol Cancer. 2015;14:104.
79. Mohri K, Nishikawa M, Takahashi N, et al. Design and development of nanosized DNA assemblies in polypod-like structures as efficient vehicles for immunostimulatory CpG motifs to immune cells. ACS Nano. 2012;6(7):5931–5940.
80. Nishikawa M, Ogawa K, Umeki Y, et al. Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery. J Control Release. 2014;180:25–32.
81. Ishii-Mizuno Y, Umeki Y, Takahashi Y, et al. Nasal delivery of Japanese cedar pollen Cryj1 by using self-gelling immunostimulatory DNA for effective induction of immune responses in mice. J Control Release. 2015;200:52–59.
82. Sakurai K, Mizu M, Shinkai S. Polysaccharide-polynucleotide complexes. 2. Complementary polynucleotide mimic behavior of the natural polysaccharide schizophyllan in the macromolecular complex with single-stranded RNA and DNA. Biomacromolecules. 2001;2(3):641–650.
83. Kobiyama K, Aoshi T, Narita H, et al. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. Proc Natl Acad Soc U S A. 2014;111(8):3086–3091.
84. Heit A, Schmitz F, O’Keeffe M, et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol. 2005;174(7):4373–4380.
85. Cho HJ, Takabayashi K, Cheng P-M, et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activation by a T-helper cell-independent mechanism. Nat Biol. 2000;18(5):509–514.
86. Suzuki M, Ohta N, Min W-P, et al. Immunotherapy with CpG DNA conjugated with T-cell epitope peptide of an allergenic Cry j 2 protein is useful for control of allergic conditions in mice. Int Immunopharcol. 2007;7(1):46–54.
87. Karuraki Y, Fujimura T, Masuda K, et al. Induction of Th1 immune responses to Japanese cedar pollen allergen (Cry j 1) in mice immunized with Cryj1 conjugated with CpG oligodeoxynucleotide. Comp Immunol Microbiol Infect Dis. 2011;34(2):157–161.
88. Salem AK. A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies. Immunotherapy. 2014;6(11):1161–1163.
89. Shirota H, Klinman DM. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol Immunother. 2011;60(5):659–669.
90. Gungor B, Yagci FC, Tincer G, et al. CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity. Sci Transl Med. 2014;6:235ra61.
91. Joshi VB, Adamcakova-Dodd A, Jing X, et al. Development of poly(lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS J. 2014;16(5):975–985.
92. Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15(1):85–93.
93. Nikitczuk KP, Schloss RS, Yarmush ML, Lattime EC. PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival. J Caner Ther. 2013;4(1):280–290.
94. Lv S, Wang J, Dou S, et al. Nanoparticles encapsulating hepatitis B virus cytosine–phosphate–guanosine induce therapeutic immunity against HBV infection. Hepatology. 2014;59(2):385–394.
95. Speiser DE, Schwarz K, Baumgaertner P, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010;33(8):848–858.
96. Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39(4):562–570.
97. Beeh K-M, Kanniess F, Wagner F, et al. The novel TLR-9 agonist QβG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol. 2013;131(3):866–874.
98. Kundig TM, Klimek L, Schendzieloz P, Renner WA, Senti G, Bachmann MF. Is the allergen really needed in allergy immunotherapy? Curr Treat Options Allergy. 2015;2(1):72–82.
99. Casale TB, Cole J, Beck E, et al. CYT003, a TLR9 agonist, in persistent allergic asthma – a randomized placebo-controlled Phase 2B study. Allergy. 2015;70(9):1160–1169.
100. Kwon S, Kim D, Park B, et al. Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncology Rep. 2013;29(2):735–740.
101. Kwon S, Kim Y-E, Park J-A, Kim D-S, Kwon H-J, Lee Y. Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model. BMB Rep. 2014;47(4):215–220.
102. Erikci E, Gursel M, Gursel I. Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes. Biomaterials. 2011;32(6):1715–1723.
103. Slutter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA. Adjuvant effect of cationic liposomes and CpG depends on administration route. J Control Release. 2011;154(2):123–130.
104. Chen S, Zhang H, Shi X, Wu H, Hanagata N. Microfluidic generation of chitosan/CpG oligodeoxynucleotide nanoparticles with enhanced cellular uptake and immunostimulatory properties. Lab Chip. 2014;14(11):1842–1849.
105. Manoharan Y, Ji Q, Yamazaki T, et al. Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-α. Int J Nanomed. 2012;7:3625–3635.
106. Zhang H, Feng S, Yan T, Zhi C, Gao X-D, Hanagata N. Polyethyleneimine-functionalized boron nitride nanospheres as efficient carriers for enhancing the immunostimulatory effect of CpG oligodeoxynucleotides. Int J Nanomed. 2015;10:5343–5353.
107. Zhang H, Chen S, Zhi C, Yamazaki T, Hanagata N. Chitosan-coated boron nitride nanoparticles enhance delivery of CpG oligodeoxynucleotides and induction of cytokines. Int J Nanomed. 2013;8:1783–1793.
108. Xu Y, Claiden P, Zhu Y, Morita H, Hanagata N. Effect of amino groups of mesoporous silica nanoparticles on CpG oligodeoxynucleotide delivery. Sci Technol Adv Mater. 2015;16(4):045006.
109. Wei M, Chen N, Li J, et al. Polyvalent immunostimulatory nanoagents with self-assembled CpG oligonucleotide-conjugated gold nanoparticles. Angew Chem Int Ed. 2012;51(5):1202–1206.
110. Zhang H, Yamazaki T, Zhi C, Hanagata N. Identification of a boron nitride nanosphere-binding peptide for the intracellular delivery of CpG oligodeoxynucleotides. Nanoscale. 2012;4(20):6343–6450.
111. Ballester M, Jeanbart L, de Titta A, et al. Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice. Sci Rep. 2015;5:14274.
112. Jeanbalt L, Ballester M, de Titta A, et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res. 2014;2(5):436–447.
113. Zhao D, Alizadeh D, Zhang L, et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin Cancer Res. 2011;17(4):771–782.
114. Hirsh V, Paz-Ares L, Boyer M, et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(19):2667–2674.
115. Manegold C, van Zandwijk N, Szczesna A, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2012;23(1):72–77.